Conjunctivitis, also known as pink eye, is a conjunctival inflammation. It is brought on by bacteria, viruses, toxins, and allergies, including coronaviruses, the most frequent reason being allergic conjunctivitis (AC), which is brought on by exposure to pollutants like pollen, animal hair, or mold. The primary contributor to it is the linkage of immunoglobulin E caused by allergens and receptors on stimulated conjunctival mast cells. As a consequence, mast cells are degranulated, along with the release of histamine, cytokines, chemokines, and lipid mediators. The particular eye tissues impacted and the immune mechanism(s) (both local and systemic) that are involved all play a role in the clinical course, length, intensity, and co-morbidities. It frequently occurs in conjunction with allergic rhinitis, also known as allergic rhino-conjunctivitis and other allergy conditions. Atopic keratoconjunctivitis, giant papillary conjunctivitis, seasonal and perennial conjunctivitis, and vernal keratoconjunctivitis are the different types of allergic conjunctivitis. Ocular allergies are frequently misdiagnosed and undertreated, despite the emergence of innovative therapeutic strategies. This review focuses on several previously published studies to discuss the available therapeutic options for treating allergic conjunctivitis as well as the potential targets for the therapies. The association of conjunctivitis with COVID-19, along with recent patents and research, has also been explored.

Allergic Conjunctivitis; Seasonal and Perennial Allergic Conjunctivitis; Vernal Keratoconjunctivitis; Atopic Keratoconjunctivitis; Giant Papillary Conjunctivitis; Treatments; Potential Targets

1. Candia OA, Alvarez LJ. Overview of electrolyte and fluid transport across the conjunctiva. In: Dartt DA, Besharse JC, Dana R (editors). Encyclopedia of the eye. Cambridge: Academic Press; 2010. p. 252–260. doi: 10.1016/B978-0-12-374203-2.00052-X.

2. Hashmi MF, Gurnani B, Benson S. Conjunctivitis [Internet]. Tampa/St. Petersburg: StatPearls; 2022 [updated 2022 May 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541034/.

3. La Rosa M, Lionetti E, Reibaldi M, et al. Allergic conjunctivitis: A comprehensive review of the literature. Italian Journal of Pediatrics 2013; 39(1): 18. doi: 10.1186/1824-7288-39-18.

4. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmologica 2008; 86(1): 5–17. doi: 10.1111/j.1600-0420.2007.01006.x.

5. Azari AA, Barney NP. Conjunctivitis: A systematic review of diagnosis and treatment. Jama 2013; 310(16): 1721–1729. doi: 10.1001/jama.2013.280318.

6. Yeu E, Hauswirth S. A review of the differential diagnosis of acute infectious conjunctivitis: Implications for treatment and management. Clinical Ophthalmology 2020; 14: 805–813. doi: 10.2147/OPTH.S236571.

7. O’Brien TP, Jeng BH, McDonald M, Raizman MB. Acute conjunctivitis: Truth and misconceptions. Current Medical Research and Opinion 2009; 25(8): 1953–1961. doi: 10.1185/03007990903038269.

8. Bielory L, Meltzer EO, Nichols KK, et al. An algorithm for the management of allergic conjunctivitis. Allergy & Asthma Proceedings 2013; 34(5): 408–420. doi: 10.2500/aap.2013.34.3695.

9. Sahdev AK, Sethi B, Singh A, et al. Conjunctivitis: Types, diagnosis and treatment under different therapies. Asian Journal of Pharmacy and Pharmacology 2018; 4(4): 421–428. doi: 10.31024/ajpp.2018.4.4.7.

10. Riggioni Víquez S, Riggioni Víquez C, Ribó González P, et al. Diagnosis and management of allergic conjunctivitis. Current Treatment Options in Allergy 2018; 5: 256–265. doi: 10.1007/s40521-018-0165-5.

11. Bielory L, Delgado L, Katelaris CH, et al. ICON: Diagnosis and management of allergic conjunctivitis. Annals of Allergy, Asthma & Immunology 2020; 124(2): 118–134. doi: 10.1016/j.anai.2019.11.014.

12. O’Brien TP. Allergic conjunctivitis: An update on diagnosis and management. Current Opinion in Allergy and Clinical Immunology 2013; 13(5): 543–549. doi: 10.1097/ACI.0b013e328364ec3a.

13. Leonardi A, Castegnaro A, La Gloria Valerio A, Lazzarini D. Epidemiology of allergic conjunctivitis: Clinical appearance and treatment patterns in a population-based study. Current Opinion in Allergy and Clinical Immunology 2015; 15(5): 482–488. doi: 10.1097/ACI.0000000000000204.

14. Dupuis P, Lisa Prokopich C, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy, Asthma & Clinical Immunology 2020; 16(1): 5. doi: 10.1186/s13223-020-0403-9.

15. Iordache A, Boruga M, Mușat O, et al. Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis)-review. Romanian Journal of Ophthalmology 2022; 66(1): 8–12. doi: 10.22336/rjo.2022.3.

16. Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye 2004; 18: 345–351. doi: 10.1038/sj.eye.6700675.

17. Feizi S, Javadi MA, Alemzadeh-Ansari M, et al. Management of corneal complications in vernal keratoconjunctivitis: A review. The Ocular Surface 2021; 19: 282–289. doi: 10.1016/j.jtos.2020.10.005.

18. Chigbu DI, Labib BA. Immunopharmacology in vernal keratoconjunctivitis: Current and future perspectives. Pharmaceuticals 2021; 14(7): 658. doi: 10.3390/ph14070658.

19. Allansmith MR, Ross RN. Ocular allergy. Clinical & Experimental Allergy 1988; 18(1): 1–13. doi: 10.1111/j.1365-2222.1988.tb02837.x.

20. Vichyanond P, Pacharn P, Pleyer U, Leonardi A. Vernal keratoconjunctivitis: A severe allergic eye disease with remodeling changes. Pediatric Allergy and Immunology 2014; 25(4): 314–322. doi: 10.1111/pai.12197.

21. Rao SK, Meenakshi S, Srinivasan B, Baluswamy S. Perilimbal bulbar conjunctival pigmentation in vernal conjunctivitis: Prospective evaluation of a new clinical sign in an Indian population. Cornea 2004; 23(4): 356–359. doi: 10.1097/00003226-200405000-00008.

22. Kumar S. Vernal keratoconjunctivitis: A major review. Acta ophthalmologica 2009; 87(2): 133–147. doi: 10.1111/j.1755-3768.2008.01347.x.

23. Addis H, Jeng BH. Vernal keratoconjunctivitis. Clinical Ophthalmology 2018; 12: 119–123. doi: 10.2147/OPTH.S129552.

24. Hossain IT, Sanghi P, Manzouri B. Pharmacotherapeutic management of atopic keratoconjunctivitis. Expert Opinion on Pharmacotherapy 2020; 21(14): 1761–1769. doi: 10.1080/14656566.2020.1786534.

25. Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: A review. Journal of the American Academy of Dermatology 2014; 70(3): 569–575. doi: 10.1016/j.jaad.2013.10.036.

26. Jabbehdari S, Starnes TW, Kurji KH, et al. Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. The Ocular Surface 2019; 17(2): 303–309. doi: 10.1016/j.jtos.2018.12.002.

27. Daniell M, Constantinou M, Vu HT, Taylor HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. The British Journal of Ophthalmology 2006; 90(4): 461–464. doi: 10.1136/bjo.2005.082461.

28. Sy H, Bielory L. Atopic keratoconjunctivitis. Allergy & Asthma Proceedings 2013; 34(1): 33–41. doi: 10.2500/aap.2013.34.3612.

29. Kenny SE, Tye CB, Johnson DA, Kheirkhah A. Giant papillary conjunctivitis: A review. The Ocular Surface 2020; 18(3): 396–402. doi: 10.1016/j.jtos.2020.03.007.

30. Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunology and Allergy Clinics of North America 2008; 28(1): 83–103. doi: 10.1016/j.iac.2007.11.001.

31. Takamura E, Uchio E, Ebihara N, et al. Japanese guidelines for allergic conjunctival diseases 2017. Allergology International 2017; 66(2): 220–229. doi: 10.1016/j.alit.2016.12.004.

32. Bielory L. Allergic conjunctivitis and the impact of allergic rhinitis. Current Allergy and Asthma Reports 2010; 10: 122–134. doi: 10.1007/s11882-010-0087-1.

33. Lai Y, Sundar G, Ray M. Surgical treatment outcome of medically refractory huge giant papillary conjunctivitis. American Journal of Ophthalmology Case Reports 2017; 8: 22–24. doi: 10.1016/j.ajoc.2017.09.002.

34. Kabra N, Gupta S. Cryotherapy in giant papillary conjunctivitis with shield’s ulcer. Delhi Journal of Ophthalmology 2020; 30(3): 75–77. doi: 10.7869/djo.533.

35. Villegas BV, Benitez-del-Castillo JM. Current knowledge in allergic conjunctivitis. Turkish Journal of Ophthalmology 2021; 51(1): 45–54. doi: 10.4274/tjo.galenos.2020.11456.

36. Baroody FM, Naclerio RM. Nasal-ocular reflexes and their role in the management of allergic rhinoconjunctivitis with intranasal steroids. The World Allergy Organization Journal 2011; 4(1 Suppl): S1–5. doi: 10.1097/WOX.0b013e3181f32dcd.

37. Singhal D, Sahay P, Maharana PK, et al. Vernal keratoconjunctivitis. Survey of Ophthalmology 2019; 64(3): 289–311. doi: 10.1016/j.survophthal.2018.12.001.

38. Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and eye: A review of ophthalmic manifestations of COVID-19. Indian Journal of Ophthalmology 2021; 69(3): 488–509. doi: 10.4103/ijo.IJO_297_21.

39. Robbins SG, Detrick B, Hooks JJ. Ocular tropisms of murine coronavirus (strain JHM) after inoculation by various routes. Investigative Ophthalmology & Visual Science 1991; 32(6): 1883–1893.

40. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmology 2020; 138(5): 575–578. doi: 10.1001/jamaophthalmol.2020.1291.

41. Scalinci SZ, Battagliola ET. Conjunctivitis can be the only presenting sign and symptom of COVID-19. IDCases 2020; 20: e00774. doi: 10.1016/j.idcr.2020.e00774.

42. Day M. Covid-19: Ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368: m1086. doi: 10.1136/bmj.m1086.

43. Güemes-Villahoz N, Burgos-Blasco B, García-Feijoó J, et al. Conjunctivitis in COVID-19 patients: Frequency and clinical presentation. Graefe’s Archive for Clinical and Experimental Ophthalmology 2020; 258(11): 2501–2507. doi: 10.1007/s00417-020-04916-0.

44. Lalitha P, Venkatesh Prajna N, Gunasekaran R, et al. Deep sequencing analysis of clinical samples from patients with acute infectious conjunctivitis during the COVID-19 delta surge in Madurai, India. Journal of Clinical Virology 2022; 157: 105318. doi: 10.1016/j.jcv.2022.105318.

45. Babushkin AE, Saitova GR, Matyukhina EN. Viral conjunctivitis as the first sign of COVID-19 infection (clinical observation). Vestnik Oftalmologii 2022; 138(1): 52–56. doi: 10.17116/oftalma202213801152.

46. Varu DM, Rhee MK, Akpek EK, et al. Conjunctivitis preferred practice pattern®. Ophthalmology 2019; 126(1): P94–P169. doi: 10.1016/j.ophtha.2018.10.020.

47. Stokes TC, Feinberg G. Rapid onset of action of levocabastine eye‐drops in histamine‐induced conjunctivitis. Clinical & Experimental Allergy 1993; 23(9): 791–794. doi: 10.1111/j.1365-2222.1993.tb00368.x.

48. Abelson MB, Shetty S, Korchak M, et al. Advances in pharmacotherapy for allergic conjunctivitis. Expert Opinion on Pharmacotherapy 2015; 16(8): 1219–1231. doi: 10.1517/14656566.2015.1040760.

49. Randall KL, Hawkins CA. Antihistamines and allergy. Australian Prescriber 2018; 41(2): 41–45. doi: 10.18773/austprescr.2018.013.

50. Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy, Asthma & Clinical Immunology 2019; 15: 61. doi: 10.1186/s13223-019-0375-9.

51. Cutolo CA, Barabino S, Bonzano C, Traverso CE. The use of topical corticosteroids for treatment of dry eye syndrome. Ocular Immunology and Inflammation 2019; 27(2): 266–275. doi: 10.1080/09273948.2017.1341988.

52. Holland EJ, Fingeret M, Mah FS. Use of topical steroids in conjunctivitis: A review of the evidence. Cornea 2019; 38(8): 1062–1067. doi: 10.1097/ICO.0000000000001982.

53. Kari O, Saari KM. Updates in the treatment of ocular allergies. Journal of Asthma and Allergy 2010; 3: 149–158. doi: 10.2147/JAA.S13705.

54. Zhang T, Finn DF, Barlow JW, Walsh JJ. Mast cell stabilisers. European Journal of Pharmacology 2016; 778: 158–168. doi: 10.1016/j.ejphar.2015.05.071.

55. Weisenthal RW, Daly MK, de Freitas D, et al. (editors). 2020-2021 basic and clinical science course(tm) (BCSC), section 8: External disease and cornea. San Francisco: American Academy of Ophthalmology; 2020. p. 533.

56. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunology and Allergy Clinics of North America 2008; 28(1): 43–58. doi: 10.1016/j.iac.2007.12.005.

57. Elieh Ali Komi D, Rambasek T, Bielory L. Clinical implications of mast cell involvement in allergic conjunctivitis. Allergy 2018; 73(3): 528–539. doi: 10.1111/all.13334.

58. Liu YC, Lin MTY, Ng AHC, et al. Nanotechnology for the treatment of allergic conjunctival diseases. Pharmaceuticals 2020; 13(11): 351. doi: 10.3390/ph13110351.

59. Davis S. Topical treatment options for allergic conjunctivitis. South African Family Practice 2015; 57(4): 10–15. doi: 10.4102/safp.v57i4.4326.

60. Leonardi A, Silva D, Perez Formigo D, et al. Management of ocular allergy. Allergy 2019; 74(9): 1611–1630. doi: 10.1111/all.13786.

61. Kimchi N, Bielory L. The allergic eye: Recommendations about pharmacotherapy and recent therapeutic agents. Current Opinion in Allergy and Clinical Immunology 2020; 20(4): 414–420. doi: 10.1097/ACI.0000000000000669.

62. Wilson DJ, Schutte SM, Abel SR. Comparing the efficacy of ophthalmic NSAIDs in common indications: A literature review to support cost-effective prescribing. The Annals of Pharmacotherapy 2015; 49(6): 727–734. doi: 10.1177/1060028015574593.

63. Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. Allergy & Rhinology 2016; 7(2): 107–114. doi: 10.2500/ar.2016.7.0158.

64. Rodrigues EB, Farah ME, Bottós JM, Aggio FB. Nonsteroidal anti-inflammatory drugs in the treatment of retinal diseases. Developments in Ophthalmology 2016; 55: 212–220. doi: 10.1159/000431197.

65. Liu YC, Ng XW, Teo EPW, et al. A biodegradable, sustained-released, tacrolimus microfilm drug delivery system for the management of allergic conjunctivitis in a mouse model. Investigative Ophthalmology & Visual Science 2018; 59(2): 675–684. doi: 10.1167/iovs.17-23066.

66. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008; 115(6): 988–992. doi: 10.1016/j.ophtha.2007.07.025.

67. Awara A, Atiba A, Helal D, Elbedewy H. Effectiveness of subconjunctival cyclosporine in treatment of acute allergic conjunctivitis in a rat-model. Clinical Ophthalmology 2020; 14: 431–435. doi: 10.2147/OPTH.S244287.

68. D’Arienzo PA, Leonardi A, Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clinical Therapeutics 2002; 24(3): 409–416. doi: 10.1016/s0149-2918(02)85042-1.

69. Noble S, McTavish D. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Drugs 1995; 50(6): 1032–1049. doi: 10.2165/00003495-199550060-00009.

70. Gomes PJ, Ciolino JB, Arranz P, et al. Efficacy of once-daily ophthalmic bilastine for the treatment of allergic conjunctivitis: A dose-finding study. Journal of Investigational Allergology and Clinical Immunology 2022. doi: 10.18176/jiaci.0800.

71. Mishra GP, Tamboli V, Jwala J, Mitra AK. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Patents on Inflammation & Allergy Drug Discovery 2011; 5(1): 26–36. doi: 10.2174/187221311794474883.

72. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye & Contact Lens 2004; 30(1): 10–13. doi: 0.1097/01.icl.0000092071.82938.46.

73. Bielory L. Ocular allergy guidelines: A practical treatment algorithm. Drugs 2002; 62(11): 1611–1634. doi: 10.2165/00003495-200262110-00004.

74. Chigbu DI, Coyne AM. Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis. Clinical Ophthalmology 2015; 9: 1215–1225. doi: 10.2147/OPTH.S63790.

75. Wu MMS, Yau GSK, Lee JWY, et al. Retrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese. The Scientific World Journal 2014; 2014: 396987. doi: 10.1155/2014/396987.

76. Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opinion on Pharmacotherapy 2013; 14(11): 1449–1465. doi: 10.1517/14656566.2013.802773.

77. Calderon MA, Penagos M, Sheikh A, et al. Cochrane review: Sublingual immunotherapy for treating allergic conjunctivitis. Evidence‐Based Child Health: A Cochrane Review Journal 2012; 7(3): 1041–1154. doi: 10.1002/ebch.1851.

78. Passalacqua G, Pasquali M, Ariano R, et al. Randomized double‐blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006; 61(7): 849–854. doi: 10.1111/j.1398-9995.2006.01095.x.

79. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. The Journal of Allergy and Clinical Immunology 1999; 104(5): 964–968. doi: 10.1016/s0091-6749(99)70076-x.

80. Casale TB, Stokes JR. Immunotherapy: What lies beyond. Journal of Allergy and Clinical Immunology 2014; 133(3): 612–619. doi: 10.1016/j.jaci.2014.01.007.

81. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proceedings of the National Academy of Sciences 2008; 105(46): 17908–17912. doi: 10.1073/pnas.0803725105.

82. Anastassov G, Changoer L (inventors). Apirx Pharmaceutical Usa LLC. (assignee). Ophthalmic solutions for glaucoma and conjunctivitis treatment. US patent. 9,844,530B1. 2017 Dec 19.

83. Young S, Braddy T, Gitu Machatha S, et al. (inventors). Aldeyra Therapeutics Inc. (assignee). Treatment of allergic eye conditions with cyclodextrins. US patent. 10,426,790B2. 2019 Oct 1.

84. Okazaki N (inventor). Dr. C Medical Medicine Co., Ltd. (assignee). Medicinal preparation and medical instrument. US patent. 20,210,052,488A1. 2021 Feb 25.

85. Chambon P, Hua G (inventors). Association Pour La Recherche À L’igbmc (ari) (assignee). Non-steroidal selective glucocorticoid receptor agonistic modulators (SEGRAMs) and uses thereof. US patent. 20,190,151,283A1. 2019 May 30.

86. Strem B (inventor). Okogen Inc. (assignee). Viral conjunctivitis treatment using ranpirnase and/or amphinase. US patent. 20,220,265,783A1. 2022 Aug 25.

87. Jarrett P, El-Hayek R, Jarrett TS, et al. (inventors). Incept LLC. (assignee). Drug delivery from hydrogels. US patent. 20,220,370,419A1. 2022 Nov 24.

88. Jain S, Musunuri K (inventors). Advaite LLC. (assignee). Treatment and diagnosis of ocular surface disorders. US patent. 20,210,322,457A1. 2021 Oct 21.

89. Capriotti J, Capriotti K, Pelletier J, Stewart K (inventors). Veloce Biopharma, LLC. (assignee). Novel ophthalmic composition and method of use. WO patent. 2,019,135,779A1. 2019 Jul 11.

90. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. Journal of Allergy and Clinical Immunology 2014; 133(2): 448–460. doi: 10.1016/j.jaci.2013.10.048.

91. Liu B, Escalera J, Balakrishna S, et al. TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis. The FASEB Journal 2013; 27(9): 3549–3563. doi: 10.1096/fj.13-229948.

92. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). The Journal of Immunology 2011; 186(7): 4234–4243. doi: 10.4049/jimmunol.1003668.

93. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 2019; 58(Suppl 1): i43–i54. doi: 10.1093/rheumatology/key276.

94. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergology International 2006; 55(4): 379–386. doi: 10.2332/allergolint.55.379.

95. Mandell KJ, Clark D, Chu DS, et al. Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: Model for corticosteroid replacement. Journal of Ocular Pharmacology and Therapeutics 2020; 36(10): 732–739. doi: 10.1089/jop.2020.0056.

96. Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. Journal of Ocular Pharmacology and Therapeutics 2021; 37(4): 193–199. doi: 10.1089/jop.2020.0087.

97. Sánchez-Tabernero S, Fajardo-Sanchez J, Weston-Davies W, et al. Dual inhibition of complement component 5 and leukotriene B4 by topical rVA576 in atopic keratoconjunctivis: TRACKER phase 1 clinical trial results. Orphanet Journal of Rare Diseases 2021; 16(1): 270. doi: 10.1186/s13023-021-01890-6.

98. McLaurin EB, Evans D, Repke CS, et al. Phase 3 randomized study of efficacy and safety of a dexamethasone intracanalicular insert in patients with allergic conjunctivitis. American Journal of Ophthalmology 2021; 229: 288–300. doi: 10.1016/j.ajo.2021.03.017.

99. Clark D, Cavanagh B, Shields AL, et al. Clinically relevant activity of the novel rasp inhibitor reproxalap in allergic conjunctivitis: The Phase 3 ALLEVIATE trial. American Journal of Ophthalmology 2021; 230: 60–67. doi: 10.1016/j.ajo.2021.04.023.

100. de Blay F, Gherasim A, Domis N, et al. Efficacy of N‐acetyl aspartyl glutamic acid versus fluorometholone for treating allergic conjunctivitis in an environmental exposure chamber. Clinical & Experimental Allergy 2022; 52(9): 1091–1100. doi: 10.1111/cea.14130.

101. Anesi SD, Tauber J, Nguyen QD, et al. Lirentelimab for severe and chronic forms of allergic conjunctivitis. The Journal of Allergy and Clinical Immunology 2022; 150(3): 631–639. doi: 10.1016/j.jaci.2022.03.021.

102. Pall B, Gomes P, Yi F, Torkildsen G. Management of ocular allergy itch with an antihistamine-releasing contact lens. Cornea 2019; 38(6): 713–717. doi: 10.1097/ICO.0000000000001911.

103. Schneider U, Hollands P. Intravenous gold-induced autologous serum injection therapy (Go ACT®) as a new treatment for seasonal pollen-based allergies. European Review for Medical and Pharmacological Sciences 2021; 25(11): 4121–4127. doi: 10.26355/eurrev_202106_26055.

104. El-Emam GA, Girgis GNS, Hamed MF, et al. Formulation and pathohistological study of mizolastine-solid lipid nanoparticles-loaded ocular hydrogels. International Journal of Nanomedicine 2021; 16: 7775–7799. doi: 10.2147/IJN.S335482.